Search Results - "Kenealy, M."

This result is not displayed to guests.
Login for full access.

When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?

Authors: Bird, R. J. Kenealy, M. Forsyth, C. et al.

Source: Internal Medicine Journal. Apr2012, Vol. 42 Issue 4, p450-455. 6p. 1 Chart.

Energy use in pig production: An examination of current Iowa systems.

Authors: Lammers, P. J. Kenealy, M. D. Kliebenstein, J. B. et al.

Source: Journal of Animal Science. Mar2012, Vol. 90 Issue 3, p1056-1068. 13p.

Current status of new drugs for the treatment of patients with multiple myeloma.

Authors: Kenealy, M. Prince, H. M.

Source: Internal Medicine Journal. Dec2006, Vol. 36 Issue 12, p781-789. 9p. 2 Diagrams, 1 Chart.

13 THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL.

Authors: Kenealy, M. Benson, W. Stevenson, W. et al.

Source: Leukemia Research. Apr2015 Supplement 1, Vol. 39, pS5-S5. 1p.

P-272 The combination of azacitidine and lenalidomide is deliverable without unexpected toxicity; interim safety results of the ALLG MDS4 randomised trial.

Authors: Kenealy, M. Seymour, J.F. Benson, W. et al.

Source: Leukemia Research. May2013 Supplement, Vol. 37, pS145-S145. 1p.

176 Do genome scale methylation changes in patients with MDS treated with azacitidine and thalidomide correlate with response to treatment?

Authors: Kenealy, M. Wong, N. Maksimovic, J. et al.

Source: Leukemia Research. Jan2011 Supplement 1, Vol. 35, pS69-S69. 1p.

60 Results of a phase II study of thalidomide (Thai) and azacitidine (Aza) in patients with clinically advanced myelodysplastic syndromes (MDS)

Authors: Kenealy, M. Giri, P. Filshie, R. et al.

Source: Leukemia Research. Jan2011 Supplement 1, Vol. 35, pS22-S22. 1p.

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study.

Authors: Germing, U Lauseker, M Hildebrandt, B et al.

Source: Leukemia (08876924). Jun2012, Vol. 26 Issue 6, p1286-1292. 7p. 7 Charts, 5 Graphs.

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.

Authors: Carney, D. A. Westerman, D. A. Tam, C. S. et al.

Source: Leukemia (08876924). Dec2010, Vol. 24 Issue 12, p2056-2062. 7p. 2 Charts, 1 Graph.

P-276 High doses of eltrombopag are well-tolerated in conjunction with azacitidine and demonstrate encouraging activity in patients with MDS and AML.

Authors: Dickinson, M. Herbert, K. Sardjono, C. et al.

Source: Leukemia Research. May2013 Supplement, Vol. 37, pS147-S147. 1p.

195 Biomarkers for response to lenalidomide (LEN) treatment in patients with myelodysplastic syndromes (MDS)

Authors: Burbury, K. Gambell, P. Neeson, P. et al.

Source: Leukemia Research. Jan2011 Supplement 1, Vol. 35, pS77-S77. 1p.

P028 Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q)

Authors: Germing, U. Hildebrandt, B. Symeonidis, A. et al.

Source: Leukemia Research. May2009 Supplement 1, Vol. 33, pS74-S74. 1p.

Immunosuppression-Associated Peripheral T-Cell Lymphoma.

Authors: Cliff ERS Kenealy M

Source: The New England journal of medicine [N Engl J Med] 2026 Jun 18; Vol. 394 (23), pp. 2356. Date of Electronic Publication: 2026 Jun 13.

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE; In Process

Favorable outcomes of DDX41-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide.

Authors: Tiong IS Stevenson WS Wall M et al.

Corporate Authors: Tiong IS Stevenson WS Wall M et al.

Source: EJHaem [EJHaem] 2023 Aug 25; Vol. 4 (4), pp. 1212-1215. Date of Electronic Publication: 2023 Aug 25 (Print Publication: 2023).

Publication Type: Journal Article

Journal Info: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101761942 Publication Model: eCollection Cited Medium: Internet ISSN: 2688-6146 (Electronic) Linking ISSN: 26886146 NLM ISO Abbreviation: EJHaem Subsets: PubMed not MEDLINE

Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs.

Authors: Thoms JAI Yan F Hampton HR et al.

Source: Nature communications [Nat Commun] 2025 May 13; Vol. 16 (1), pp. 4451. Date of Electronic Publication: 2025 May 13.

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS).

Authors: Chee L Ritchie D Ludford-Menting M et al.

Source: European journal of haematology [Eur J Haematol] 2022 Apr; Vol. 108 (4), pp. 342-353. Date of Electronic Publication: 2022 Feb 03.

Publication Type: Journal Article

Journal Info: Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE

Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.

Authors: McQuilten ZK Busija L Seymour JF et al.

Corporate Authors: McQuilten ZK Busija L Seymour JF et al.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2022 Mar; Vol. 63 (3), pp. 676-683. Date of Electronic Publication: 2021 Dec 17.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.

Authors: Horvath N Spencer A Kenealy M et al.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2019 Sep; Vol. 60 (9), pp. 2122-2133. Date of Electronic Publication: 2019 Feb 19.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).

Authors: Kenealy M Patton N Filshie R et al.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2017 Feb; Vol. 58 (2), pp. 298-307. Date of Electronic Publication: 2016 Jun 07.

Publication Type: Clinical Trial, Phase II; Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE